AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca PLC (AZN) reports that Chief Executive Officer Pascal Soriot purchased additional equity in the company. On September 14, 2026, Soriot bought 60,000 AstraZeneca Ordinary Shares with a nominal value of US$0.25 each at a price of £121.02 per share on the LON market. The transaction is disclosed as a purchase by a Person Discharging Managerial Responsibilities in accordance with the EU Market Abuse Regulation as it forms part of UK law.
ASTRAZENECA PLC (AZN) reports that its Chief Financial Officer, Dr Aradhana Sarin, acquired 73 ordinary shares on September 14, 2026, through the vesting of dividend equivalent awards linked to her 2021 AstraZeneca Performance Share Plan award.
These dividend equivalents related to the first interim dividend for 2026 and vested separately from the main 2021 award, which vested on August 17, 2026. Shares were withheld to meet tax obligations, and the fair market value used for tax purposes was £114.60 per ordinary share.
AstraZeneca PLC (AZN) reports that Non-Executive Chair of the Board Michel Demaré purchased AstraZeneca ordinary shares. On September 14, 2026, he acquired 2,500 Ordinary Shares of US$0.25 nominal value each at a price of £121.213296 per share on the London market.
The notification is made as a Director/Person Discharging Managerial Responsibilities (PDMR) transaction in accordance with the EU Market Abuse Regulation as it forms part of UK law.
AstraZeneca PLC (AZN) reported that the SERENA-4 Phase III trial of its oral SERD Etcamah (camizestrant) plus palbociclib in 1st-line treatment of ER-positive, HER2-negative advanced breast cancer did not meet its primary endpoint of progression-free survival versus anastrozole plus palbociclib, although a numerical improvement was seen.
The safety profile of Etcamah with palbociclib was consistent with known profiles and no new safety concerns were identified. Etcamah remains approved in multiple major markets for ESR1-mutated HR-positive, HER2-negative advanced breast cancer based on SERENA-6, and is being further studied in large CAMBRIA-1 and CAMBRIA-2 Phase III trials in early breast cancer.
ASTRAZENECA PLC (AZN) reported insider share acquisitions by officer Sharma Mani, Senior Vice President, Group Controller and Head of Global Finance Services. On August 8, 2026, Mani acquired 20.233 Ordinary Shares through automatic dividend reinvestment linked to a Restricted Share Plan. On September 8, 2026, Mani acquired 1 Ordinary Share under a Share Incentive Plan. No Rule 10b5-1 trading plan is reported.
ASTRAZENECA PLC (AZN) reports positive high-level Phase III DeLLphi-305 results showing that Imfinzi (durvalumab) plus Amgen’s Imdelltra (tarlatamab) achieved a statistically significant and highly clinically meaningful improvement in overall survival versus Imfinzi alone as 1st-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC).
The combination also significantly improved progression-free survival and objective response rate, with a safety profile consistent with the known profiles of each medicine and no new safety signals identified. These data will be presented at an upcoming medical meeting and shared with global regulatory authorities.
AstraZeneca PLC (AZN) reports that Etcamah (camizestrant) combined with a CDK4/6 inhibitor has received accelerated FDA approval in the US for 1st-line treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with an emergent ESR1 mutation detected during aromatase inhibitor plus CDK4/6 inhibitor therapy.
The approval is based on the Phase III SERENA-6 trial, where the Etcamah combination reduced the risk of disease progression or death by 56% versus an aromatase inhibitor plus CDK4/6 inhibitor (hazard ratio 0.44; median progression-free survival 16.0 vs 9.2 months). A pre-planned analysis showed a statistically significant PFS2 benefit of 25.7 vs 19.1 months (hazard ratio 0.63), while overall survival data are still maturing.
The safety profile was consistent with known profiles of the component medicines, with no new safety concerns and low, similar discontinuation rates in both arms. Concurrently, the FDA approved a companion diagnostic ctDNA test to detect emerging ESR1 resistance mutations, supporting a ctDNA-guided strategy to switch endocrine therapy before clinical disease progression.
AstraZeneca PLC (AZN) reported the admission of additional ordinary shares to trading on the London Stock Exchange Main Market. The company issued and admitted 10,072 ordinary shares of $0.25 each between 1 August 2026 and 31 August 2026 under existing employee share schemes and a prior block admission dated 29 January 2021.
Following this admission, AstraZeneca states that the total number of ordinary shares in issue is 1,551,043,461, which are fully fungible with the existing ordinary shares. No prospectus or supplementary prospectus was required for this admission.
ASTRAZENECA PLC (AZN) reports its total voting rights as of 31 August 2026. The issued share capital with voting rights consists of 1,551,043,461 ordinary shares of US$0.25 each, and no shares are held in Treasury. Accordingly, the total number of voting rights is 1,551,043,461. Shareholders may use this figure as the denominator when calculating whether they must notify their interest, or any change in their interest, under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
ASTRAZENECA PLC (AZN) reports that its wholly owned subsidiary AstraZeneca Finance LLC has had four euro-denominated bond series with an aggregate nominal amount of EUR 2.55 billion admitted to trading on the Main Market of the London Stock Exchange on 1 September 2026.
The notes comprise EUR 700 million 3.402% Notes due 1 March 2030, EUR 600 million 3.652% Notes due 1 September 2032, EUR 500 million 3.923% Notes due 1 September 2035, and EUR 750 million 4.169% Notes due 1 September 2038, all issued under a Base Prospectus dated 9 June 2026 and targeted at professional clients and eligible counterparties only.